European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Rating neurologic impairment in multiple sclerosis

1983 • 14,011 citations

New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

1983 • 7,404 citations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 • 1,903 citations

Intensive Immunosuppression in Progressive Multiple Sclerosis

1983 • 813 citations

Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability

1999 • 713 citations

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

1998 • 504 citations

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis

1999 • 490 citations

A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis

1987 • 465 citations

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis

1996 • 444 citations

Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

2000 • 412 citations

Natural history of multiple sclerosis

1994 • 410 citations

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1993 • 378 citations

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

1991 • 373 citations

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1997 • 365 citations

Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

1998 • 334 citations

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1997 • 280 citations

The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis

1995 • 251 citations

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

1994 • 243 citations

Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation

1998 • 226 citations

Copolymer 1 acts against the immunodominant epitope 82–100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

1999 • 191 citations

A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1991 • 176 citations

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

1998 • 166 citations

Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images

1997 • 159 citations

Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS

2000 • 142 citations

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1996 • 105 citations

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis

1997 • 105 citations

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

1998 • 98 citations

The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflections

1996 • 94 citations

Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis

1998 • 79 citations

Current immunotherapy in multiple sclerosis

1998 • 15 citations